Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beneficial effects of amiloride on progression of chronic kidney disease (A-CKD)
2022-500692-31-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Amiloride (MODAMIDE) arm with Placebo arm (2 arms). Primary endpoints: Urine C3a, Urine soluble C5-9-sTCC/MAC and 2 more. Planned start Nov 2023; status: authorised.
02
Drugs
amiloride
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-500692-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500692-31-00.